Pediatric pulmonary arterial hypertension is a disease of invisible hemodynamic burden. A child with well-managed PAH on triple combination therapy can attend school, play with siblings, and report dyspnea only with vigorous exertion — while the pulmonary arterioles are progressively remodeling, the right ventricle is operating under afterload three to five times normal, and the window for lung transplant is advancing. The families caring for these children navigate a clinical reality in which the daily evidence of their eyes — a child functioning, eating, sleeping — does not match the urgency of the clinical decisions being made.
Spanish for pediatric pulmonary arterial hypertension clinic nurses begins with recognizing three structural gaps between what families observe and what the clinical team is managing at the molecular and hemodynamic level. First: why are three drugs needed when each one dilates blood vessels? If one vasodilator dilates, why not use the best one and simplify? Second: why is an invasive catheterization with sedation required every 12 to 18 months when a non-invasive echocardiogram provides information at every visit? Third: why is transplant evaluation initiated while the child is still functionally stable? The answers to each question require making an invisible biological mechanism visible — the three-pathway independence of pulmonary arteriolar remodeling, the precision gap between echocardiographic estimation and catheter measurement of PVR, and the two-to-three-year timeline that forces transplant evaluation to precede hemodynamic decompensation by years.
The three conversations in this post take place in Houston, San Antonio, and Dallas, in the pediatric pulmonary hypertension programs of three children’s hospitals. Each involves a family that is engaged, medically informed by months or years of clinic experience, and genuinely puzzled by a recommendation that appears inconsistent with what they observe in their child’s daily life. Each involves a nurse explaining the invisible mechanism in bilingual Spanish-English dialogue.
Scenario 1: Mateo Rivera-Espinoza — Houston, Texas
Pediatric PAH nurse Ana Morales-García and the parents who cannot understand why all three drugs are required when each seems to do the same thing
Mateo is nine years old. He was born in Houston to Lucía Rivera-Torres, thirty-four, a dental hygienist, and Carlos Espinoza-García, thirty-seven, an electrician. He was a healthy toddler who began showing decreased exercise tolerance at age six — unable to keep up with peers at the park, stopping to rest after short sprints that other children sustained without difficulty. His parents initially attributed this to asthma. At age seven, a workup at the pediatric pulmonology clinic revealed a right heart catheterization showing mean pulmonary artery pressure 52 mmHg, pulmonary vascular resistance index 12 Wood units × m², and cardiac index 2.4 L/min/m². Idiopathic Group 1 pulmonary arterial hypertension was diagnosed after vasoreactivity testing showed no response to inhaled nitric oxide.
Over eighteen months, the treatment team has sequentially escalated Mateo’s therapy: first sildenafil 10 mg three times daily, then bosentan 62.5 mg twice daily added at three months, then subcutaneous treprostinil initiated at 6 ng/kg/min and slowly uptitrated to 30 ng/kg/min over the following year. His most recent catheterization showed mPAP 38 mmHg, PVRi 7.8 Wood units × m², and CI 3.1 L/min/m² — significant hemodynamic improvement on triple therapy. His six-minute walk distance has improved from 268 to 401 meters. He attends third grade and participates in quiet play.
Today’s visit is a quarterly nurse-led review focused on medication adherence and subcutaneous treprostinil site management. At the end of the visit, as Lucía is reviewing the medication list, she raises the question she and Carlos have been discussing at home.
Lucía: “Quiero preguntarle algo que hemos pensado mucho. Mateo está mejor — el catéter lo confirmó. Y él está tomando tres medicamentos al mismo tiempo. Entiendo que todos ayudan. Pero los tres hacen lo mismo, ¿no? Dilatan los vasos del pulmón. ¿No se podría simplificar a uno o dos para reducir los efectos secundarios y la carga de tantas pastillas?”
(I want to ask something we have been thinking about a lot. Mateo is doing better — the catheterization confirmed it. And he is taking three medications at the same time. I understand they all help. But they all do the same thing, right? They dilate the lung vessels. Could we not simplify to one or two to reduce side effects and the burden of so many pills?)
Carlos adds: “Y el treprostinil es el que más trabajo da — el sitio subcutáneo, el dolor de la infusión, la bomba. Si los tres hacen lo mismo, ¿el treprostinil es el más complicado y el que podríamos quitar primero?”
(And treprostinil is the one that is the most work — the subcutaneous site, the infusion pain, the pump. If all three do the same thing, is treprostinil the most complicated one and the first one we could remove?)
Nurse Ana Morales-García nods and pulls her chair forward. “Esa pregunta es muy razonable, y entiendo perfectamente por qué lo están pensando — tres medicamentos para una sola enfermedad parece mucho si todos hacen lo mismo. Pero aquí está la parte que los quiero explicar bien: los tres no hacen lo mismo. Cada uno trabaja en una ruta diferente, una ruta completamente separada dentro de los vasos del pulmón de Mateo. Y la enfermedad de Mateo está usando las tres rutas al mismo tiempo.”
(That question is very reasonable, and I completely understand why you are thinking about it — three medications for a single disease seems like a lot if they all do the same thing. But here is the part I want to explain to you clearly: the three do not do the same thing. Each one works on a different pathway, a completely separate pathway inside Mateo's lung vessels. And Mateo's disease is using all three pathways at the same time.)
Lucía: “¿Tres rutas diferentes?”
(Three different pathways?)
“Sí. Para explicarlo, déjenme hablarles de cómo está construido un vaso del pulmón. Los vasos pequeños del pulmón — las arteriolas — tienen una capa de músculo en la pared. Ese músculo puede contraerse y relajarse. Cuando se contrae demasiado, el vaso se estrecha y la presión sube. En la enfermedad de Mateo, ese músculo se está contrayendo demasiado y además está creciendo — la pared del vaso se engrósa con el tiempo. Hay tres señales moleculares separadas que le dicen a ese músculo que se contraiga y que crezca. Tres señales completamente distintas, usando receptores distintos y mensajeros químicos distintos dentro de las células.”
(Yes. To explain it, let me tell you how a lung vessel is constructed. The small vessels of the lung — the arterioles — have a layer of muscle in the wall. That muscle can contract and relax. When it contracts too much, the vessel narrows and pressure rises. In Mateo's disease, that muscle is contracting too much and is also growing — the vessel wall thickens over time. There are three separate molecular signals that tell that muscle to contract and to grow. Three completely distinct signals, using different receptors and different chemical messengers inside the cells.)
Carlos: “¿Y cada medicamento trabaja en una de esas señales?”
(And each medication works on one of those signals?)
“Exactamente. La primera señal se llama la ruta del óxido nítrico. Las células que cubren el interior del vaso producen normalmente una sustancia llamada óxido nítrico. Esa sustancia entra al músculo del vaso y activa una cadena de reacciones que termina en relajación del músculo — el vaso se abre. Pero para que esa cadena funcione, necesita una molécula llamada cGMP. Y hay una enzima llamada PDE5 cuyo trabajo es destruir el cGMP. En la enfermedad de Mateo, la PDE5 está más activa de lo normal — destruye el cGMP demasiado rápido, y la señal de relajación no llega. El sildenafil bloquea la PDE5. Le dice a esa enzima: para. No destruyas el cGMP. Así el cGMP se acumula, la cadena de relajación funciona, y el músculo se relaja por esa ruta. Solo por esa ruta — el sildenafil no toca las otras dos.”
(Exactly. The first signal is called the nitric oxide pathway. The cells that line the inside of the vessel normally produce a substance called nitric oxide. That substance enters the vessel muscle and activates a chain of reactions that ends in muscle relaxation — the vessel opens. But for that chain to work, it needs a molecule called cGMP. And there is an enzyme called PDE5 whose job is to destroy cGMP. In Mateo's disease, PDE5 is more active than normal — it destroys cGMP too fast, and the relaxation signal does not get through. Sildenafil blocks PDE5. It tells that enzyme: stop. Do not destroy cGMP. That way cGMP accumulates, the relaxation chain works, and the muscle relaxes through that pathway. Only through that pathway — sildenafil does not touch the other two.)
Lucía: “¿Y el bosentan? ¿Cuál es su ruta?”
(And bosentan? What is its pathway?)
“La segunda ruta se llama la ruta de la endotelina. La endotelina-1 es una sustancia que las células del interior del vaso producen en exceso en la enfermedad de Mateo. La endotelina es muy potente: les dice a las células del músculo que se contraigan y que se multipliquen, que crezcan. También activa una señal que engrosa la pared del vaso produciendo las lesiones permanentes que queremos evitar. Tiene sus propios receptores en el músculo del vaso — receptores totalmente diferentes a los que usa el óxido nítrico. El bosentan bloquea esos receptores. Se sienta encima de los receptores de la endotelina y no deja que la endotelina se conecte. Si la endotelina no puede conectarse a su receptor, no puede dar la señal de contracción ni de crecimiento. Solo por esa ruta — el bosentan no toca el cGMP ni la prostaciclina.”
(The second pathway is called the endothelin pathway. Endothelin-1 is a substance that the cells inside the vessel produce in excess in Mateo's disease. Endothelin is very potent: it tells the muscle cells to contract and to multiply, to grow. It also activates a signal that thickens the vessel wall producing the permanent lesions we want to prevent. It has its own receptors in the vessel muscle — receptors completely different from those used by nitric oxide. Bosentan blocks those receptors. It sits on the endothelin receptors and does not let endothelin connect. If endothelin cannot connect to its receptor, it cannot give the contraction or growth signal. Only through that pathway — bosentan does not touch cGMP or prostacyclin.)
Carlos: “¿Y el treprostinil, la tercera?”
(And treprostinil, the third one?)
“La tercera ruta es la de la prostaciclina. En condiciones normales, las células del interior de los vasos producen una sustancia llamada prostaciclina. La prostaciclina tiene el efecto contrario a la endotelina: relaja el músculo, reduce el crecimiento de las células, previene la formación de coágulos dentro del vaso. Funciona a través de sus propios receptores — completamente diferentes a los de la endotelina y a los que usa el óxido nítrico. En la enfermedad de Mateo, las células del interior del vaso producen muy poca prostaciclina — la ruta que la naturaleza puso para proteger los vasos está produciendo muy poca señal. El treprostinil es una molécula artificial que imita la prostaciclina — se conecta exactamente a los mismos receptores que la prostaciclina natural y produce los mismos efectos de relajación y protección. Como se administra de forma continua por vía subcubtánea, está activo las 24 horas del día. Solo trabaja por esa ruta — no toca la PDE5 ni los receptores de endotelina.”
(The third pathway is the prostacyclin pathway. Under normal conditions, the cells inside the vessels produce a substance called prostacyclin. Prostacyclin has the opposite effect from endothelin: it relaxes the muscle, reduces cell growth, prevents clot formation inside the vessel. It works through its own receptors — completely different from those of endothelin and from those used by nitric oxide. In Mateo's disease, the cells inside the vessel produce very little prostacyclin — the pathway that nature put in place to protect the vessels is producing very little signal. Treprostinil is an artificial molecule that mimics prostacyclin — it connects to exactly the same receptors as natural prostacyclin and produces the same relaxation and protection effects. Because it is administered continuously via subcutaneous infusion, it is active 24 hours a day. It only works through that pathway — it does not touch PDE5 or endothelin receptors.)
Lucía looks at the medication list slowly. “Entonces si quitamos uno de los tres — digamos el treprostinil como Carlos decía — la ruta de la prostaciclina queda sin bloquear.”
(So if we remove one of the three — say treprostinil as Carlos was saying — the prostacyclin pathway remains unblocked.)
“Exactamente. Y la enfermedad de Mateo usaría esa ruta que dejamos libre para seguir estrechando y engrosando los vasos. El sildenafil puede estar bloqueando la ruta del óxido nítrico perfectamente, y el bosentan bloqueando la endotelina perfectamente, pero si la ruta de la prostaciclina está abierta, el músculo del vaso va a recibir la señal de la tercera ruta y va a seguir creciendo por ahí. Las tres rutas son independientes. Bloquear dos no bloquea la tercera.”
(Exactly. And Mateo's disease would use that pathway we left free to continue narrowing and thickening the vessels. Sildenafil can be blocking the nitric oxide pathway perfectly, and bosentan blocking endothelin perfectly, but if the prostacyclin pathway is open, the vessel muscle will receive the signal from the third pathway and will continue growing through it. The three pathways are independent. Blocking two does not block the third.)
Carlos: “¿Y los estudios comprueban que los tres juntos funcionan mejor?”
(And do studies confirm that all three together work better?)
“Sí. Hay estudios grandes en adultos con esta misma enfermedad que muestran consistentemente que la terapia de combinación triple produce menor resistencia vascular, mejor flujo cardíaco, menos hospitalizaciones y mejor sobrevida que la terapia doble o simple. La resistencia vascular del pulmón de Mateo bajó de 12 a 7.8 con los tres medicamentos juntos. Eso es una mejora real que le reduce la carga al cortón derecho de Mateo — que es el que tiene que bombear contra esa presión alta. Quitarle uno de los tres le añadiría carga de vuelta al corazón derecho.”
(Yes. There are large studies in adults with this same disease that consistently show that triple combination therapy produces lower vascular resistance, better cardiac flow, fewer hospitalizations, and better survival than dual or single therapy. Mateo's pulmonary vascular resistance dropped from 12 to 7.8 with all three medications together. That is a real improvement that reduces the burden on Mateo's right heart — which is the one that has to pump against that high pressure. Removing one of the three would add burden back to the right heart.)
Lucía takes a breath. “Entonces el treprostinil — aunque es el más difícil de manejar — es el que está bloqueando la tercera ruta que no tiene otro medicamento. No es redundante.”
(So treprostinil — even though it is the hardest to manage — is the one blocking the third pathway that no other medication covers. It is not redundant.)
“Exactamente. No solo no es redundante — es la única cosa que está bloqueando la ruta de la prostaciclina. Si lo quitamos, esa ruta queda completamente libre. Lo que sí podemos hacer — y de hecho es algo que el equipo revisa en cada visita — es trabajar en el sitio subcubtáneo para reducir la incomodidad. Hay técnicas de rotación de sitios, ajustes de velocidad de infusión, sitios alternativos en el abdomen y el muslo que a veces son menos molestos que el brazo. No podemos eliminar el medicamento, pero sí podemos hacer el manejo más llevadero.”
(Exactly. Not only is it not redundant — it is the only thing blocking the prostacyclin pathway. If we remove it, that pathway is completely free. What we can do — and in fact the team reviews this at every visit — is work on the subcutaneous site to reduce discomfort. There are site rotation techniques, infusion rate adjustments, alternative sites on the abdomen and thigh that are sometimes less uncomfortable than the arm. We cannot eliminate the medication, but we can make the management more bearable.)
Carlos nods slowly. “No lo habíamos pensado de esa manera. Pensábamos que eran tres versiones de la misma llave, no tres llaves para tres cerraduras distintas.”
(We had not thought about it that way. We thought they were three versions of the same key, not three keys for three different locks.)
“Esa es exactamente la imagen correcta. Tres llaves para tres cerraduras separadas que la enfermedad está usando al mismo tiempo. Para bloquear la enfermedad completamente, se necesitan las tres.”
(That is exactly the right image. Three keys for three separate locks that the disease is using at the same time. To block the disease completely, all three are needed.)
Scenario 2: Valentina Cruz-Mendoza — San Antonio, Texas
Pediatric PAH nurse Elena Herrera-Vega and the parents who cannot understand why catheterization is required when the echocardiogram shows good results
Valentina is twelve years old. She was born in San Antonio to Ana Cruz-Torres, thirty-nine, a school cafeteria worker, and Roberto Mendoza-García, forty-one, a plumber. She has a history of ventricular septal defect repaired surgically at age five — a small residual muscular VSD was left unrepaired at that time and has been monitored since. Mild pulmonary arterial hypertension was detected at age nine during post-operative surveillance. She has been on bosentan 125 mg twice daily since age ten, with tadalafil 40 mg daily added at age eleven when repeat catheterization showed PVRi increase from 4.2 to 6.8 Wood units × m².
Her most recent echocardiogram, performed six weeks ago, showed estimated RVSP 48 mmHg by TR jet velocity, mild right ventricular dilation, and preserved TAPSE (tricuspid annular plane systolic excursion) of 19 mm. The echocardiographer’s report noted the findings were “unchanged compared to prior study.” The team has now scheduled a right heart catheterization for next month, twelve months after Valentina’s last catheterization. Ana and Roberto have requested a meeting with the nurse before the procedure to understand why it is necessary given the reassuring echocardiogram.
Ana begins: “La última vez que la cateterizaron fue hace un año. El ecocardiograma de hace seis semanas dijo que todo estaba igual. La ecografía le revisó el corazón, le midió la presión, y está igual que antes. Si el ecocardiograma dice que está igual, ¿no podemos postponer el catéter por otro año y hacerle otro ecocardiograma en seis meses en vez de eso? El catéter requiere sedación, y Valentina lo pasa mal esos días.”
(The last time she was catheterized was a year ago. The echocardiogram six weeks ago said everything was the same. The ultrasound checked her heart, measured her pressure, and it is the same as before. If the echocardiogram says she is the same, can we not postpone the catheter for another year and do another echocardiogram in six months instead? The catheter requires sedation, and Valentina has a hard time on those days.)
Roberto: “También nos parece que el catéter es un procedimiento más riesgoso que el ecocardiograma. Si la información que da el ecocardiograma es suficiente para saber cómo está, preferimos ese.”
(We also feel that the catheter is a riskier procedure than the echocardiogram. If the information the echocardiogram gives is sufficient to know how she is doing, we prefer that one.)
Nurse Elena Herrera-Vega takes a seat. “Voy a explicarles exactamente por qué el ecocardiograma y el catéter no son intercambiables para Valentina, aunque los dos miden el corazón. No es un tema de si uno es mejor que el otro en general — cada uno mide cosas diferentes, y las cosas que necesitamos para tomar decisiones sobre el tratamiento de Valentina son las que solo el catéter puede medir con la precisión suficiente.”
(I am going to explain to you exactly why the echocardiogram and the catheter are not interchangeable for Valentina, even though both measure the heart. It is not a question of one being better than the other in general — each measures different things, and the things we need to make decisions about Valentina's treatment are the ones only the catheter can measure with sufficient precision.)
Ana: “El ecocardiograma midió la presión: 48. ¿Eso no es suficiente?”
(The echocardiogram measured the pressure: 48. Is that not sufficient?)
“Ese número — 48 — es una estimación calculada a partir de la velocidad de un chorro de sangre en el cortón. El ecocardiograma mide la velocidad de ese chorro, y luego usa una fórmula matemática para calcular cuál podría ser la presión. El problema es el margen de error de esa estimación. Para una paciente como Valentina, el margen de error entre el número que da el ecocardiograma y la presión real que mediría el catéter puede ser de 10 a 20 puntos en cualquier dirección. Un ecocardiograma que dice 48 podría corresponder a una presión real de 35, o de 60. Esa diferencia es clínicamente enorme. A 35 mm Hg, la enfermedad está bien controlada. A 60 mm Hg, el tratamiento necesita cambiar.”
(That number — 48 — is an estimate calculated from the velocity of a blood jet in the right heart. The echocardiogram measures the velocity of that jet, and then uses a mathematical formula to calculate what the pressure might be. The problem is the margin of error of that estimate. For a patient like Valentina, the margin of error between the number the echocardiogram gives and the actual pressure the catheter would measure can be 10 to 20 points in either direction. An echocardiogram that says 48 could correspond to an actual pressure of 35, or of 60. That difference is clinically enormous. At 35 mmHg, the disease is well controlled. At 60 mmHg, the treatment needs to change.)
Roberto: “¿Y el ecocardiograma de este año dijo ‘igual que antes’. ¿Eso no significa que no empeoró?”
(And the echocardiogram this year said 'the same as before'. Does that not mean it did not worsen?)
“Aquí está el problema con esa comparación. Si el ecocardiograma del año pasado dijo 46 y este año dice 48, eso parece ‘esencialmente igual.’ Pero si el error de cada medición es de ±15 puntos, entonces ‘esencialmente igual’ en el ecocardiograma es compatible con la resistencia vascular real habéndose doblado — o habiéndose reducido a la mitad. Dos mediciones con ±15 de error comparadas entre sí no me dicen nada sobre si la resistencia real subió o bajó. Lo que el ecocardiograma puede detectar es un cambio muy grande — si la presión pasara de 48 a 80, el ecocardiograma lo vería. Pero para Valentina, el cambio que me importa detectar es uno de 6 a 12 Wood units de resistencia — un cambio que es clínicamente significativo pero que el ecocardiograma no puede distinguir del margen de error de sus propias mediciones.”
(Here is the problem with that comparison. If last year's echocardiogram said 46 and this year's says 48, that seems 'essentially the same.' But if the error of each measurement is ±15 points, then 'essentially the same' on echocardiogram is compatible with the actual vascular resistance having doubled — or having been cut in half. Two measurements with ±15 error compared to each other tell me nothing about whether actual resistance went up or down. What echocardiography can detect is a very large change — if pressure went from 48 to 80, the echocardiogram would see it. But for Valentina, the change I need to detect is one from 6 to 12 Wood units of resistance — a change that is clinically significant but that echocardiography cannot distinguish from the margin of error of its own measurements.)
Ana: “¿Y esas unidades ‘Wood’ que mencionan en los catéteres — qué miden exactamente?”
(And those 'Wood units' mentioned in catheterizations — what exactly do they measure?)
“Las unidades Wood miden la resistencia de los vasos del pulmón — cuánto esfuerzo necesita el cortón derecho para empujar la sangre a través de los vasos del pulmón. Resistencia alta = vasos estrechós = cortón derecho trabajando más de lo que debe. Resistencia baja = vasos más abiertos = cortón derecho trabajando menos. La resistencia en unidades Wood es el número que el equipo de Valentina usa para decidir si el tratamiento está funcionando o si necesita añadirse otro medicamento. Y ese número requiere tres mediciones directas que solo el catéter puede hacer: la presión media en la arteria pulmonar (directamente con el sensor), la presión de cuña — que mide cuánta presión hay en el lado de las venas del pulmón (el ecocardiograma no puede medir eso directamente) — y el flujo cardíaco, que se mide inyectando una pequeña cantidad de líquido frío y midiendo cómo cambia la temperatura en el cortón (tampoco lo puede medir el ecocardiograma con la misma precisión en pacientes con PAH). Los tres se necesitan para calcular la resistencia real.”
(Wood units measure the resistance of the lung vessels — how much effort the right heart needs to push blood through the lung vessels. High resistance = narrowed vessels = right heart working more than it should. Low resistance = more open vessels = right heart working less. Resistance in Wood units is the number Valentina's team uses to decide whether treatment is working or whether another medication needs to be added. And that number requires three direct measurements that only the catheter can make: the mean pressure in the pulmonary artery (directly with the sensor), the wedge pressure — which measures how much pressure there is on the venous side of the lungs (the echocardiogram cannot measure that directly) — and the cardiac flow, which is measured by injecting a small amount of cold fluid and measuring how temperature changes in the heart (also something echocardiography cannot measure with the same precision in PAH patients). All three are needed to calculate actual resistance.)
Roberto: “¿Y hay alguna razón más además de la resistencia?”
(And is there any other reason besides the resistance?)
“Sí. En el catéter también hacemos la prueba de vasodilatación aguda. Damos una sustancia que dilata los vasos del pulmón — normalmente es óxido nítrico inhalado — y medimos cómo responden los vasos. En un pequeño grupo de pacientes con esta enfermedad — aproximadamente el 10 al 15 por ciento — los vasos responden abriendo mucho. Eso es una respuesta positiva. Para ese grupo de pacientes, el tratamiento es completamente diferente: en vez de los tres medicamentos que tiene Mateo, ese grupo puede tratarse con altas dosis de un tipo de medicamento llamado bloqueadores de canales de calcio, que es mucho más simple de manejar y tiene mejores resultados en ese subgrupo específico. La prueba de vasodilatación aguda solo se puede hacer en el catéter. Al cateterízar a Valentina la primera vez, la prueba salió negativa — ella no es del grupo respondedor. Pero repetir el catéter también nos permite confirmar que sigue sin responder, porque en algunos pacientes eso cambia.”
(Yes. During catheterization we also perform the acute vasodilatory test. We administer a substance that dilates the lung vessels — normally inhaled nitric oxide — and measure how the vessels respond. In a small group of patients with this disease — approximately 10 to 15 percent — the vessels respond by opening greatly. That is a positive response. For that group of patients, treatment is completely different: instead of the three medications that Mateo has, that group can be treated with high doses of a type of medication called calcium channel blockers, which is much simpler to manage and has better outcomes in that specific subgroup. The acute vasodilatory test can only be performed at catheterization. When Valentina was catheterized the first time, the test was negative — she is not in the responder group. But repeating the catheterization also allows us to confirm she continues not to respond, because in some patients that changes.)
Ana is quiet for a moment. “O sea que el ecocardiograma nos da información, pero no la información que ustedes necesitan para decidir si el tratamiento de Valentina necesita cambiar.”
(So the echocardiogram gives us information, but not the information you need to decide whether Valentina's treatment needs to change.)
“Exactamente. El ecocardiograma es excelente para monitorear la estructura del cortón, el tamaño de las cámaras, el movimiento de las paredes. Para eso lo seguimos usando. Pero el número que nos permite decir ‘el tratamiento está funcionando’ o ‘necesitamos añadir un tercer medicamento’ es la resistencia vascular en unidades Wood, y eso solo el catéter lo mide con la precisión suficiente. Entendemos perfectamente que los días del catéter son díficiles para Valentina. Vamos a hablar con el equipo de anestesia sobre cómo hacer el manejo de la sedación más tolerable para ella.”
(Exactly. The echocardiogram is excellent for monitoring heart structure, chamber size, wall movement. For that we continue using it. But the number that allows us to say 'treatment is working' or 'we need to add a third medication' is vascular resistance in Wood units, and only the catheter measures that with sufficient precision. We understand perfectly that catheterization days are difficult for Valentina. We will talk with the anesthesia team about how to make sedation management more tolerable for her.)
Roberto: “Entendemos. No sabíamos que había esa diferencia en precisión. Pensábamos que la presión era la presión.”
(We understand. We did not know there was that difference in precision. We thought pressure was pressure.)
“Es la diferencia entre una estimación y una medición directa. Para muchas cosas, la estimación es suficiente. Para la PAH de Valentina, necesitamos la medición directa porque las decisiones que tomamos con ese número son demasiado importantes para basar en una estimación con ±15 de error.”
(It is the difference between an estimate and a direct measurement. For many things, the estimate is sufficient. For Valentina's PAH, we need the direct measurement because the decisions we make with that number are too important to base on an estimate with ±15 error.)
Scenario 3: Sofía García-Torres — Dallas, Texas
Pediatric PAH nurse Patricia Torres-Morales and the parents who cannot understand why lung transplant evaluation begins when their daughter still attends school
Sofía is ten years old. She was born in Dallas to Carmen García-Morales, thirty-six, who owns a hair salon, and Miguel Torres-Cruz, thirty-eight, an HVAC technician. She was diagnosed with idiopathic Group 1 PAH at age eight after progressive dyspnea on exertion was noted at a routine pediatric visit and an echocardiogram showed severe right heart dilation and estimated RVSP 70 mmHg. Right heart catheterization confirmed mPAP 58 mmHg, PVRi 15.2 Wood units × m², CI 2.1 L/min/m².
Over twenty-four months, the pulmonary hypertension team has escalated to maximum triple combination therapy: tadalafil 40 mg daily, macitentan 10 mg daily, and subcutaneous treprostinil 50 ng/kg/min. Her most recent catheterization showed mPAP 44 mmHg, PVRi 10.2 Wood units × m², CI 2.8 L/min/m². Her six-minute walk distance is 382 meters. She attends fourth grade five days a week, though with elevator access and a modified activity plan. She reports dyspnea walking quickly up stairs and playing tag — but no dyspnea at rest and no syncope. The pulmonary hypertension team classifies her as WHO functional class III despite optimal medical therapy and has recommended initiating bilateral lung transplant evaluation at the children’s hospital transplant program.
Carmen and Miguel have arrived at today’s visit visibly distressed. Carmen speaks first: “Nos dijeron en la última visita que iban a referir a Sofía para evaluación de trasplante de pulmón. No entendemos. Ella está yendo a la escuela todos los días. Sale al recreo. Juega con su hermanita en casa los fines de semana. No puede correr como los demás niños, lo sabemos. Pero está funcionando. ¿Por qué hablan de trasplante ahora si ella todavía está activa?”
(They told us at the last visit that they were going to refer Sofía for lung transplant evaluation. We do not understand. She is going to school every day. She goes out to recess. She plays with her little sister at home on weekends. She cannot run like other children, we know that. But she is functioning. Why are they talking about transplant now if she is still active?)
Miguel: “Y además el trasplante parece una decisión enorme, con riesgos grandes. Si ella todavía está yendo a la escuela, ¿por qué no esperar a que realmente lo necesite para hablar de eso?”
(And besides, transplant seems like an enormous decision, with big risks. If she is still going to school, why not wait until she truly needs it to talk about that?)
Nurse Patricia Torres-Morales draws two chairs together. “Entiendo completamente. Y quiero explicarles con exactitud por qué estamos teniendo esta conversación ahora, porque la razón no es que Sofía esté peor de lo que ven. Es que el proceso del trasplante tiene una lógica de tiempo que lo hace necesario empezar exactamente cuando Sofía todavía está bien. Les quiero explicar dos cosas: el tiempo que toma el proceso del trasplante, y lo que pasa con la enfermedad de Sofía cuando el cortón derecho llega a su límite.”
(I understand completely. And I want to explain to you precisely why we are having this conversation now, because the reason is not that Sofía is worse than you see. It is that the transplant process has a time logic that makes it necessary to start exactly when Sofía is still well. I want to explain two things: how long the transplant process takes, and what happens with Sofía's disease when the right heart reaches its limit.)
Carmen: “Díganos.”
(Tell us.)
“Primero, el tiempo. Cuando la decisión es referir para evaluación, eso no significa trasplante maana. Significa iniciar un proceso que en el mejor de los casos — si todo va bien, sin retrasos — toma entre 2 y 3 años desde hoy hasta que Sofía recibiera un trasplante. Así está dividido ese tiempo: el centro de trasplante necesita evaluar a Sofía completamente para determinar si es candidata. Eso incluye una serie de estudios — función pulmonar completa, tomografía del tórax, evaluación cardiaca detallada, evaluación nutricional, evaluación psicosocial, estudio del sueño, grupos sanguíneos, tipificación de anticuerpos. Ese proceso de evaluación toma de 6 a 12 meses. Solo después de que la evaluación está completa, Sofía puede ser listada. Una vez en lista, el tiempo de espera para un trasplante pediátrico de pulmones dobles es de 12 a 24 meses en promedio en los centros pediátricos activos, porque el trasplante pediátrico requiere encontrar un donante del tamaño correcto y del grupo sanguíneo compatible — y los donantes pediátricos son escasos. En total: 2 a 3 años desde hoy, en el mejor de los casos.”
(First, the time. When the decision is to refer for evaluation, that does not mean transplant tomorrow. It means initiating a process that in the best case — if everything goes well, without delays — takes between 2 and 3 years from today until Sofía would receive a transplant. This is how that time is divided: the transplant center needs to evaluate Sofía completely to determine whether she is a candidate. That includes a series of studies — complete pulmonary function, chest CT scan, detailed cardiac evaluation, nutritional evaluation, psychosocial evaluation, sleep study, blood typing, antibody typing. That evaluation process takes 6 to 12 months. Only after the evaluation is complete can Sofía be listed. Once listed, the wait time for a pediatric bilateral lung transplant is 12 to 24 months on average at active pediatric centers, because pediatric transplant requires finding a donor of the right size and compatible blood type — and pediatric donors are scarce. Total: 2 to 3 years from today, in the best case.)
Miguel: “2 a 3 años desde hoy.”
(2 to 3 years from today.)
“Sí. Ahora déjenme explicar lo segundo: lo que puede pasar con la enfermedad de Sofía mientras esperamos. Sofía está en lo que los médicos llamamos clase funcional III de la OMS. Eso significa que tiene limitación significativa con actividad, pero está cómoda en reposo. Va a la escuela, como bien, duerme. La enfermedad que ella tiene — presión alta en los vasos del pulmón — pone al cortón derecho a trabajar muy por encima de lo normal. El cortón derecho de Sofía se ha ido adaptando a esa carga extra con el tiempo. Se ha engrosado, se ha ampliado, ha encontrado mecanismos para compensar. Eso es por qué Sofía puede ir a la escuela y al recreo. El cortón derecho de Sofía todavía tiene reserva compensatoria.”
(Yes. Now let me explain the second thing: what can happen with Sofía's disease while we wait. Sofía is in what doctors call WHO functional class III. That means she has significant limitation with activity, but she is comfortable at rest. She goes to school, eats well, sleeps. The disease she has — high pressure in the lung vessels — puts the right heart to work far above normal. Sofía's right heart has been adapting to that extra load over time. It has thickened, has enlarged, has found mechanisms to compensate. That is why Sofía can go to school and to recess. Sofía's right heart still has compensatory reserve.)
Carmen: “¿Y esa reserva se acaba?”
(And does that reserve run out?)
“Sí. Y cuando se acaba — cuando el cortón derecho llega a su límite — el cambio no es gradual. No es que Sofía empiece a cansarse un poco más cada semana y tengamos meses para reaccionar. El cortón derecho cuando agota su reserva lo hace abruptamente. Un día la niña que iba a la escuela y jugaba en casa empieza a tener fatiga en reposo, sus pies y su barriga se hinchan porque el líquido no fluye bien, necesita oxígeno constante. Eso es lo que llamamos clase funcional IV. Y ese cambio puede ocurrir en semanas. No hay manera de predecir exactamente cuándo va a ocurrir — solo sabemos que en la clase III con la resistencia que tiene Sofía, ese riesgo existe.”
(Yes. And when it runs out — when the right heart reaches its limit — the change is not gradual. It is not that Sofía starts tiring a little more each week and we have months to react. The right heart when it exhausts its reserve does so abruptly. One day the girl who was going to school and playing at home starts having fatigue at rest, her feet and belly swell because fluid is not flowing well, she needs constant oxygen. That is what we call WHO functional class IV. And that change can happen in weeks. There is no way to predict exactly when it will happen — we only know that in class III with the resistance Sofía has, that risk exists.)
Miguel: “¿Y si llegara a clase IV, el trasplante ya no sería posible?”
(And if she were to reach class IV, would transplant no longer be possible?)
“En clase IV con fallo del cortón derecho avanzado, el trasplante se vuelve muchísimo más difícil. El cortón derecho que está fallando no puede sostener la circulación durante la cirugía de trasplante ni durante los meses de recuperación post-operatoria. Hay pacientes en clase IV que pueden recibir trasplante con soporte especial — pero la mortalidad es muchísimo mayor, y muchos no son elegibles para ese soporte. Lo que queremos evitar es que Sofía llegue a esa evaluación del trasplante en clase IV. Queremos que llegue en clase III, con el cortón derecho todavía compensado, capaz de aguantar el proceso. Por eso empezamos la evaluación ahora.”
(In class IV with advanced right heart failure, transplant becomes much, much harder. The right heart that is failing cannot sustain circulation during transplant surgery or during the months of post-operative recovery. There are patients in class IV who can receive transplant with special support — but mortality is much higher, and many are not eligible for that support. What we want to avoid is Sofía arriving at transplant evaluation in class IV. We want her to arrive in class III, with the right heart still compensated, capable of enduring the process. That is why we start the evaluation now.)
Carmen looks at Miguel. Then: “¿Empezar ahora no significa que el trasplante ocurre ahora?”
(Starting now does not mean transplant happens now?)
“No. Empezar la evaluación es exactamente eso: una evaluación. El equipo del trasplante revisa si Sofía es una candidata, y eso mismo toma meses. Si durante ese proceso la enfermedad de Sofía se estabilizara más de lo que esperamos — nueva medicación que no tenemos hoy, mejora inesperada — la decisión de listarla puede modificarse. La evaluación no es un camino sin retorno. Lo que no podemos hacer es esperar a que Sofía esté en clase IV para empezar la evaluación, porque para ese momento el proceso de 2 a 3 años todavía va a tomar el mismo tiempo — y Sofía ya no estaría en condiciones de aguantarlo.”
(No. Starting evaluation is exactly that: an evaluation. The transplant team reviews whether Sofía is a candidate, and that itself takes months. If during that process Sofía's disease stabilized more than we expect — a new medication we do not have today, unexpected improvement — the decision to list her can be modified. Evaluation is not a one-way path. What we cannot do is wait until Sofía is in class IV to start the evaluation, because by that point the 2-to-3-year process will still take the same amount of time — and Sofía would no longer be in condition to endure it.)
Miguel takes Carmen’s hand. “¿El equipo del trasplante trabaja con ustedes, o es un equipo completamente separado?”
(Does the transplant team work with you, or is it a completely separate team?)
“Trabajan en comunicación directa. El equipo de hipertensión pulmonar de Sofía — los que la conocen y la han tratado estos dos años — siguen siendo los que manejan sus medicamentos y hacen los catéteres y las evaluaciones de rutina. El equipo de trasplante se añade como un equipo paralelo que va haciendo la evaluación de elegibilidad. Los dos equipos hablan regularmente. Si hay noticias de la evaluación de trasplante que afectan las decisiones del tratamiento de hipertensión, ambos equipos lo saben. Ustedes van a conocer a los dos equipos y van a poder hacer preguntas a los dos.”
(They work in direct communication. Sofía's pulmonary hypertension team — those who have known and treated her for these two years — continues managing her medications and doing the catheterizations and routine evaluations. The transplant team is added as a parallel team that gradually conducts the eligibility evaluation. Both teams talk regularly. If there is news from the transplant evaluation that affects pulmonary hypertension treatment decisions, both teams know it. You will meet both teams and will be able to ask questions of both.)
Carmen wipes her eyes. “No es lo que esperábamos escuchar cuando llegamos. Pero entendemos por qué ahora. Empezar cuando ella todavía está bien, para que si algún día lo necesita, llegue bien.”
(It is not what we expected to hear when we arrived. But we understand why now. Start when she is still well, so that if she ever needs it, she arrives well.)
“Exactamente. Ese es el objetivo. Y hoy, esta tarde, Sofía sigue siendo la niña que va a la escuela, que juega con su hermanita, y eso no cambia con lo que hablamos hoy. La evaluación es un proceso que ocurre en paralelo con su vida normal.”
(Exactly. That is the objective. And today, this afternoon, Sofía is still the girl who goes to school, who plays with her little sister, and that does not change with what we discussed today. The evaluation is a process that occurs in parallel with her normal life.)
Frequently asked questions
How do pediatric PAH clinic nurses explain to Spanish-speaking parents why three drugs are required simultaneously when each seems to do the same thing?
The explanation requires introducing the three distinct molecular pathways in the pulmonary arteriole: the nitric oxide–cGMP pathway (targeted by PDE5 inhibitors like sildenafil and tadalafil), the endothelin-1 pathway (targeted by ERA drugs like bosentan and macitentan), and the prostacyclin–cAMP pathway (targeted by prostacyclin analogues like treprostinil). Each pathway operates through distinct receptors and second messengers in pulmonary arteriolar smooth muscle. In PAH, all three pathways simultaneously drive vasoconstriction and progressive arteriolar remodeling (smooth muscle hypertrophy, intimal proliferation, plexiform lesion formation). Suppressing one or two pathways leaves the remaining pathway(s) driving disease progression unimpeded. The AMBITION trial demonstrated 50% reduction in first clinical failure events with initial combination ERA plus PDE5i therapy vs. monotherapy. Registry data consistently show better PVR control, cardiac output, and survival on triple therapy. The key Spanish framing: three keys for three separate locks that the disease uses simultaneously — all three are needed because the disease does not stop working when one or two locks are closed.
How do pediatric PAH clinic nurses explain to Spanish-speaking parents why right heart catheterization is necessary even when the echocardiogram looks reassuring?
Echocardiographic RVSP from TR jet velocity has a systematic measurement error of ±10–20 mmHg compared to catheter-measured mPAP, and two sequential echocardiograms with this error cannot reliably detect clinically significant PVR changes in the range of 6–12 Wood units. The primary PAH management parameter — PVRi (indexed pulmonary vascular resistance) — requires direct mPAP measurement, direct PAWP measurement, and direct cardiac output measurement by thermodilution or Fick, none of which echocardiography can provide at the required precision. Additionally, acute vasoreactivity testing — which identifies the ~10–15% of Group 1 PAH patients who are calcium channel blocker responders with fundamentally different and better-prognosis treatment pathways — can only be performed at catheterization with inhaled nitric oxide challenge. Echocardiography provides excellent structural monitoring but cannot substitute for catheter-based hemodynamic precision in PAH treatment escalation and listing decisions.
How do pediatric PAH clinic nurses explain to Spanish-speaking parents why bilateral lung transplant evaluation begins when a child with PAH is still functionally stable?
Pediatric bilateral sequential lung transplant evaluation to listing takes 6–12 months; post-listing median wait time is 12–24 months due to pediatric size-matched donor scarcity; combined evaluation-to-transplant timeline is 2–3 years in the best case. WHO functional class III on maximum triple combination therapy is the internationally recognized threshold for beginning listing evaluation because the transition from compensated FC III to decompensated FC IV right heart failure in PAH is unpredictable and can occur over weeks. A child in WHO FC IV with resting dyspnea, dependent edema, and CI below 2.0 L/min/m² is often too hemodynamically unstable to survive a 12–24 month post-listing wait even on IV prostacyclin bridge therapy. The transplant evaluation does not commit the family to transplant — it opens the option while the child’s right heart still has sufficient compensatory reserve to tolerate the surgery and recovery.
What are the key clinical Spanish phrases for explaining triple combination therapy, catheterization requirements, and transplant timing to Spanish-speaking families in the pediatric PAH clinic?
For triple combination therapy: “Los tres medicamentos trabajan en rutas diferentes — no están repitiendo el mismo trabajo” (the three medications work on different pathways — they are not repeating the same work). “Si quitamos uno, la ruta que no está bloqueada sigue engrosando los vasos” (if we remove one, the unblocked pathway continues thickening the vessels). For catheterization: “El ecocardiograma estima la presión con un margen de error — no es la medición directa que necesitamos para las decisiones de tratamiento” (echocardiogram estimates pressure with a margin of error — it is not the direct measurement we need for treatment decisions). “La resistencia de los vasos — el número que más importa — solo se puede calcular con los datos del catéter” (vessel resistance — the most important number — can only be calculated with catheter data). For transplant timing: “El trasplante pediátrico tarda 2 a 3 años desde la evaluación hasta la cirugía — ese proceso hay que empezarlo mientras el cortón todavía está compensado” (pediatric transplant takes 2 to 3 years from evaluation to surgery — that process must be started while the heart is still compensated). “Si esperamos a que empeore para empezar, ya no va a tener la reserva para aguantar el proceso” (if we wait for worsening before starting, she will no longer have the reserve to endure the process).
What are the most important communication challenges specific to Spanish-speaking families in the pediatric PAH outpatient clinic that standard handouts do not address?
Three structural disconnects drive the communication challenges. First: the apparent functional redundancy of three drugs that all dilate blood vessels vs. the actual molecular specificity of three independent vasodilatory pathways each driving arteriolar remodeling separately — a family who understands the three-key-three-lock structure will maintain triple therapy adherence through difficult periods; a family that thinks the drugs are redundant will be permanently tempted to simplify. Second: the learned trust in echocardiography vs. the specific precision gap that echocardiography has for the one parameter (PVRi) driving all PAH escalation decisions — the nurse’s task is to honor the family’s valid trust in echocardiography while explaining this specific limitation without undermining confidence in the test generally. Third: the daily evidence of a child functioning vs. the invisible hemodynamic trajectory and the unpredictable threshold of RV decompensation — the transplant conversation requires the family to look 2–3 years forward into a scenario their child’s current daily life gives no evidence for, and making the timeline math concrete is the only communication tool that can make that forward projection visible.
Pediatric pulmonary arterial hypertension clinic nursing requires managing the gap between visible function and invisible hemodynamic burden across three domains simultaneously. The family that leaves today’s triple-therapy conversation understanding why each drug is non-substitutable will not quietly discontinue the most burdensome one. The family that understands why catheterization cannot be replaced by echocardiography will not negotiate its interval away in the interest of sparing their child sedation. The family that understands the transplant timeline logic will not defer evaluation until their child is already in decompensated right heart failure.
In all three conversations, the families in this post started from a reasonable premise — three drugs seem redundant; echocardiography seems sufficient; transplant seems premature — and arrived at a different conclusion not because they were wrong to ask but because the clinical team added the biological layer their intuition could not access. The bilingual nurse who can deliver that layer in the language the family thinks in — Spanish, with the idioms and the directness and the willingness to sit at the bedside until the question is fully answered — is the practitioner these families need.
For related reading on complex communication in pediatric specialty clinics, see Spanish for pediatric chronic kidney disease clinic nurses (pre-emptive transplant timing, protein restriction, phosphate binder initiation) and Spanish for pediatric cystic fibrosis clinic nurses (why PERT continues after Trikafta, why airway clearance continues with normal FEV1). For adult lung transplant and advanced heart failure settings, see Spanish for heart failure clinic nurses — transplant pathway. The 50 Spanish ED phrases PDF covers the acute presentations that precede many of these chronic-disease conversations. Our full free practice library is available without login. For more long-form clinical-Spanish posts, visit the ClinicaLingo blog.